FR2233038A1 - Thrombosis treatment - by oral administration of a protease - Google Patents

Thrombosis treatment - by oral administration of a protease

Info

Publication number
FR2233038A1
FR2233038A1 FR7319828A FR7319828A FR2233038A1 FR 2233038 A1 FR2233038 A1 FR 2233038A1 FR 7319828 A FR7319828 A FR 7319828A FR 7319828 A FR7319828 A FR 7319828A FR 2233038 A1 FR2233038 A1 FR 2233038A1
Authority
FR
France
Prior art keywords
protease
patient
doses
enzymes
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7319828A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNERFIELD IRVING US
Original Assignee
INNERFIELD IRVING US
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNERFIELD IRVING US filed Critical INNERFIELD IRVING US
Priority to FR7319828A priority Critical patent/FR2233038A1/en
Publication of FR2233038A1 publication Critical patent/FR2233038A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Method for treating thrombosis in a patient comprises administering orally a series of large doses of protease each dose equiv. to 50-500 mg. trypsin at 30 min-2 hourly intervals until the euglobulin clotlysis activity of the patient is reduced to about half of the corresponding value before treatment. Increased fibrinolysis in the general circulation of the patient without the side effects associated with parenteral administration of enzymes. Enzymes may be trysin, papain, proteases from B. subtilis or Aspergillus oryzae. Prophylactic doses may be given using less massive doses and longer intervals between administration.
FR7319828A 1973-05-30 1973-05-30 Thrombosis treatment - by oral administration of a protease Withdrawn FR2233038A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7319828A FR2233038A1 (en) 1973-05-30 1973-05-30 Thrombosis treatment - by oral administration of a protease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7319828A FR2233038A1 (en) 1973-05-30 1973-05-30 Thrombosis treatment - by oral administration of a protease

Publications (1)

Publication Number Publication Date
FR2233038A1 true FR2233038A1 (en) 1975-01-10

Family

ID=9120309

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7319828A Withdrawn FR2233038A1 (en) 1973-05-30 1973-05-30 Thrombosis treatment - by oral administration of a protease

Country Status (1)

Country Link
FR (1) FR2233038A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170115A1 (en) * 1984-07-20 1986-02-05 Kao Corporation Thrombus dissolvent
EP0345750A2 (en) * 1988-06-08 1989-12-13 Otsuka Pharmaceutical Co., Ltd. Polyfunctional protease
EP0431811A1 (en) * 1989-11-24 1991-06-12 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD Thrombolytic agents
WO2007047205A2 (en) * 2005-10-11 2007-04-26 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of pai-1

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170115A1 (en) * 1984-07-20 1986-02-05 Kao Corporation Thrombus dissolvent
EP0345750A2 (en) * 1988-06-08 1989-12-13 Otsuka Pharmaceutical Co., Ltd. Polyfunctional protease
EP0345750A3 (en) * 1988-06-08 1992-06-03 Otsuka Pharmaceutical Co., Ltd. Polyfunctional protease
US5425942A (en) * 1988-06-08 1995-06-20 Otsuka Pharamceutical Co., Ltd. Polyfunctinal protease
EP0431811A1 (en) * 1989-11-24 1991-06-12 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD Thrombolytic agents
WO2007047205A2 (en) * 2005-10-11 2007-04-26 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of pai-1
WO2007047205A3 (en) * 2005-10-11 2007-10-04 Amano Enzyme Usa Co Ltd Enzyme inhibitors of pai-1
US8066991B2 (en) 2005-10-11 2011-11-29 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of PAI-1

Similar Documents

Publication Publication Date Title
IE41064L (en) Peptides having lh-rh/fsh-rh activity
ES8606493A1 (en) Fibronolytically active hybrid protein, process for its preparation and pharmaceutical composition.
ES442579A1 (en) Effervescent enteric coated L-dopa formulation and method of using the same
GB1382056A (en) Moulding apparatus
DE69010199T2 (en) THERAPEUTIC AGENT.
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
DE69333639D1 (en) Trypsininhibitoren
FR2233038A1 (en) Thrombosis treatment - by oral administration of a protease
IE40793L (en) Therapeutic stocking.
GB1341794A (en) Medicament for the treatment of hepatic disorders
FR2096712A1 (en) Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
ATE42466T1 (en) USE OF SACCHAROMYCES YEASTS IN THE MANUFACTURE OF A MEDICATION FOR PREVENTING OR TREATMENT OF PSEUDOMEMBRANCOLITIS.
FR2215944A1 (en) Extracts of human placenta - free of proteases, and contg. histaminase, kininases and monoamine-oxidases for treating allergies
EP0235904A3 (en) Treatment of allergy with thymopentin
GB1417074A (en) Process for producing ethanol-assimilating yeast
BE802078A (en) Oxytocin and desamino-oxytocin compsns - for treatment of impotence in males
DK0659079T3 (en) Transdermal therapeutic system with pentylenetetrazole as active substance.
DE59808541D1 (en) EXTENSION OF THE EXPRESSION OF TRANSGENIC PROTEINS BY IMMUNODODULATING TREATMENT WITH 15-DEOXYSPERGUALIN
FR2012015A1 (en) Toothpastes contng b subtilis protease
FR2181507A1 (en) Animal and vegetable proteolysates prepn - for treatment of undernutrition
ES428172A1 (en) 5-Pivaloyloxy-5-(1-phenylethyl) barbituric acid
UA10053A (en) Method for treatment of miscarriage
JPS533534A (en) Local anesthetics
FR2081578A1 (en) Effervescent enzyme mixture/sorbitol compsns - for treatment of digestive disorders
SU682234A1 (en) Preparation for prevention and elimination of side effects with antituberculous therapy "kupir"

Legal Events

Date Code Title Description
ST Notification of lapse